Cytokinetics Reports First Quarter 2022 Financial Results
Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten, to be Presented at Heart Failure 2022 on May 23, 2022 Continued Launch...
Source: globenewswire.com
Multicenter Exercise Tolerance Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Multicenter Exercise Tolerance Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Multicenter Exercise Tolerance Evaluation Today - Breaking & Trending Today
Experimental heart failure drug has little impact on exercise tolerance
Heart failure patients taking the investigational drug omecamtiv mecarbil, which has been previously shown to improve long-term outcomes, see little impact on their ability to exercise compared to a placebo, according to a study supported by the Duke Clinical Research Institute.
Source: news-medical.net
Investigational Drug for Heart Failure has Little Impact on Exercise Tolerance
Heart failure patients taking the investigational drug omecamtiv mecarbil, which has been previously shown to improve long-term outcomes, see little impact on t
Source: newswise.com
Cytokinetics Announces Topline Results From METEORIC-HF
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction Results Will Be Presented in Late Breaking Clinical Trial Session at the American... | February 15, 2022
Source: marketscreener.com